Acetic Acid

Acetic Acid

SCHEMBL3153227

CC(=O)O.CCn1ncnc1CN

nearest known ligand 0.33

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO

The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
HCAR3 P49019 1/20 0.33
KDM1A O60341 1/20 0.32
NPC1 O15118 1/20 0.32
KDM4E B2RXH2 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
XDH P47989 1/20 0.30
HTT P42858 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Acetic Acid SCHEMBL3153220 0.72 MEN1 (0.32) KDM1ANPC1SMN1; SMN2XDHHTT
SCHEMBL403843 0.71 MEN1 (0.32) NPC1XDH
SCHEMBL15942756 0.70 KDM1A (0.33) KDM1AXDHHTT
Hydrochloric Acid SCHEMBL25212839 0.66 SMN1; SMN2 (0.51) NPC1KDM4ESMN1; SMN2
SCHEMBL24015577 0.62 SMN1; SMN2 (0.42) KDM4ESMN1; SMN2HTT
SCHEMBL14825920 0.61 L3MBTL1 (0.46) HCAR3KDM4ESMN1; SMN2
SCHEMBL24129339 0.60 HTT (0.30) HTT
SCHEMBL24717114 0.60 HTT (0.30) HTT
SCHEMBL15156739 0.59 LMNA (0.47) KDM4E
Acetic Acid SCHEMBL540945 0.59 P2RX7 (0.40) KDM4ESMN1; SMN2HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1546107-B1 COX-2 INHIBITING PYRIDINE DERIVATIVES GLAXO GROUP LTD (GB) 2010-03-31 EP disclosed
US-7446117-B2 Cox-2 inhibiting pyridine derivatives GLAXO GROUP LIMITED (GB) 2008-11-04 US disclosed
US-20060040988-A1 Cox-2 Inhibiting pyridine derivatives GLAXO GROUP LIMITED (GB) 2006-02-23 US disclosed
EP-1546107-A1 COX-2 INHIBITING PYRIDINE DERIVATIVES GLAXO GROUP LIMITED (GB) 2005-06-29 EP disclosed
WO-2004024691-A1 COX-2 INHIBITING PYRIDINE DERIVATIVES GLAXO GROUP LIMITED (GB) 2004-03-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060040988-A1 Cox-2 Inhibiting pyridine derivatives PTGS2, PTGES2, PTGS1 HCAR3 2591/4885KDM1A 2831/4885NPC1 3085/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.